Cencora, Inc. (LON:0HF3)
291.52
+1.28 (0.44%)
At close: Jul 25, 2025
Cencora Revenue
Cencora had revenue of $75.45B USD in the quarter ending March 31, 2025, with 10.29% growth. This brings the company's revenue in the last twelve months to $310.23B, up 12.18% year-over-year. In the fiscal year ending September 30, 2024, Cencora had annual revenue of $293.96B with 12.12% growth.
Revenue (ttm)
$310.23B
Revenue Growth
+12.18%
P/S Ratio
0.17
Revenue / Employee
$6.74M
Employees
46,000
Market Cap
41.88B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 293.96B | 31.79B | 12.12% |
Sep 30, 2023 | 262.17B | 23.59B | 9.89% |
Sep 30, 2022 | 238.59B | 24.60B | 11.50% |
Sep 30, 2021 | 213.99B | 24.09B | 12.69% |
Sep 30, 2020 | 189.89B | 10.30B | 5.74% |
Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Oxford Nanopore Technologies | 183.19M |
Cencora News
- 23 days ago - Cencora Announces Date and Time for Third Quarter Fiscal 2025 Earnings Release - Business Wire
- 2 months ago - Cencora Elects Lori J. Ryerkerk to Its Board of Directors - Business Wire
- 2 months ago - Cencora Continues To Deliver As A Healthcare Distributor With Further Growth Signs - Seeking Alpha
- 2 months ago - Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update - Benzinga
- 2 months ago - Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Specialty Products Despite Mixed Q2 Earnings - Benzinga
- 2 months ago - Cencora, Inc. (COR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Cencora raises annual profit forecast on strong demand for specialty drugs - Reuters
- 2 months ago - Cencora Reports Fiscal 2025 Second Quarter Results - Business Wire